(Alliance News) - Mereo BioPharma Group PLC on Tuesday reported additional endpoint data from its phase 2b dose-ranging Asteroid clinical study of setrusumab, an anti-sclerostin antibody.
The AIM-listed company, which develops medicines for rare and specialty diseases, said this additional endpoint data builds on the previously identified dose-dependent bone-building effect of setrusumab.
"Based upon our review of the comprehensive data set from the phase 2b Asteroid study, these additional prespecified analyses support our previous conclusions that setrusumab is building bone at the lumbar spine and is increasing bone strength at multiple peripheral sites in adult osteogenesis imperfecta patients," said Alastair MacKinnon, chief medical officer of Mereo.
Osteogenesis imperfecta is a rare disorder characterised by fragile bones and reduced bone mass with no approved treatments, Mereo noted.
MacKinnon added: "To this end, we have made additional progress on the regulatory front, including a positive recent meeting with the European Medicines Agency, and are currently preparing for a type B end-of-phase 2 meeting with the US Food & Drug Administration, scheduled for the first quarter of 2020."
Mereo shares were trading 2.6% higher in London on Tuesday at 39.00 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.